Kamyshnikov V S
Klin Lab Diagn. 1994(3):19-22.
Disorders of cholesterol-acceptor and cholesterol-transporting properties of antiatherogenic lipoproteins are associated with changes in etherification and fractional composition of high-density lipoprotein (HDLP) cholesterol. The said metabolic shifts prompted us to develop a new method for assessment of the cholesterol coefficient of plasma lipoprotein spectrum atherogenicity calculated by the formula: (CS--alpha-CS)/alpha-CS.(ECS/FCS), where alpha-CS, ECS, and FCS are total, ether-bound, and free HDLP cholesterols, respectively. For detection of atherogenic disorders assessment of HDLP loading with ether-bound cholesterol is recommended, as well as of dyslipoproteinemia, from the ratio of atherogenic lipoproteins and HDLP2, of lipoprotein cholesterols of these two classes, and of the type and severity of dys-alpha-lipoproteinemia from HDLP2/HDLP3 ratio. A reduced value of this ratio is a sensitive indicator of disorders in antiatherogenesis metabolic system leading to impaired cholesterol outflow from the tissues. Efficacy of diagnosis of atherosclerosis by each of the suggested methods is higher than that of the prototype method. Authors' certificates for invention of these methods were granted.
抗动脉粥样硬化脂蛋白的胆固醇受体和胆固醇转运特性紊乱与高密度脂蛋白（HDLP）胆固醇的醚化和组分变化有关。上述代谢变化促使我们开发一种新的方法来评估血浆脂蛋白谱动脉粥样硬化性的胆固醇系数，该系数通过以下公式计算：(CS - α - CS)/α - CS·(ECS/FCS)，其中α - CS、ECS和FCS分别为总HDLP胆固醇、醚结合HDLP胆固醇和游离HDLP胆固醇。为了检测动脉粥样硬化性疾病，建议评估HDLP与醚结合胆固醇的结合情况，以及血脂蛋白异常，即通过动脉粥样硬化性脂蛋白与HDLP2的比例、这两类脂蛋白胆固醇的比例，以及根据HDLP2/HDLP3比例评估异常α - 脂蛋白血症的类型和严重程度。该比例降低是抗动脉粥样硬化代谢系统紊乱的敏感指标，会导致组织中胆固醇流出受损。每种建议方法对动脉粥样硬化的诊断效能均高于原型方法。这些方法的发明已获得作者证书。
